MediHealth Pharmaceuticals
MHP
Biopharmaceutical company focused on developing innovative treatments for rare diseases.
MHP · QUARTERLY FINANCIALS
Key Financial Metrics
As of Q4 2024 · YoY change where prior-year period is available · USD millions for revenue, net income, market cap, assets, and liabilities · EPS in USD · shares outstanding and P/E as reported
Revenue
$3.2B
—
Net Income
$720.0M
—
Market Cap
$45.0B
—
Total Assets
$15.0B
—
Total Liabilities
$6.0B
—
Shares Outstanding
300,000,000
—
Earnings Per Share
$2.4
—
P/E Ratio
62.5
—
MHP · QUARTERLY FINANCIALS
Revenue & Earnings
Quarterly · Q3 2024 – Q4 2024 · Values in USD millions
- Net Income
- Revenue
- Expenses
MHP · QUARTERLY FINANCIALS
Market Cap & Total Assets
Quarterly · Q3 2024 – Q4 2024 · Values in USD millions
- Market Cap
- Total Assets
MHP · QUARTERLY FINANCIALS
Profitability
Quarterly · Q3 2024 – Q4 2024 · EPS in USD · P/E ratio (dimensionless)
- EPS
- P/E ratio
MHP · QUARTERLY FINANCIALS
Financial History
Quarterly · Q3 2024 – Q4 2024 · Values in USD millions · Changes · YoY
| Metric | Q3 2024 | Q4 2024 |
|---|---|---|
| Revenue | $2.95B— | $3.20B— |
| Net income | $650.00M— | $720.00M— |
| Total assets | $14.50B— | $15.00B— |
| Total liabilities | $5.80B— | $6.00B— |
| Market cap | $42.00B— | $45.00B— |
| Shares outstanding | 300,000,000— | 300,000,000— |
| EPS | $2.17— | $2.40— |
| P/E ratio | 64.52— | 62.50— |